Lorazepam: Nursing Drug Guide, Respiratory Depression & NCLEX Review

Lorazepam is a Schedule IV benzodiazepine supplied as oral tablets (0.5 mg, 1 mg, and 2 mg per labeling), oral concentrate, and IV injection for status epilepticus. Verify strength, route, and indication on every pass—IV seizure dosing and rate limits differ from oral anxiety dosing.

Common U.S. brand example: Ativan. Generic lorazepam is widely dispensed. Do not interchange with other benzodiazepines (diazepam, alprazolam, clonazepam) without prescriber and pharmacy verification—potency, duration, and taper plans differ.

Lorazepam tablets are indicated for management of anxiety disorders or short-term relief of anxiety symptoms, including anxiety associated with depressive symptoms (everyday stress alone usually does not require an anxiolytic per labeling). Lorazepam injection is indicated for treatment of status epilepticus per IV labeling—do not assume oral tablets are interchangeable for active seizures. Use the lowest effective dose for the shortest duration and reassess usefulness when used beyond four months per tablet labeling.

↔On a small screen, swipe or scroll sideways to see the full table.

Lorazepam is a benzodiazepine that enhances GABA activity at GABA_A receptors, producing anxiolysis, sedation, and anticonvulsant effects. After oral dosing, peak plasma concentrations occur in about 2 hours; mean half-life of unconjugated lorazepam is about 12 hours, with inactive lorazepam glucuronide about 18 hours—shorter than diazepam but still clinically relevant across overlapping shifts and PRN stacking. Lorazepam is metabolized by glucuronidation without an active CNS metabolite. High single doses show little appreciable respiratory effect in healthy volunteers per labeling, but combined opioids, alcohol, or pulmonary disease markedly increase respiratory depression risk. Nurses must treat respiratory rate, oxygenation, and sedation as primary safety endpoints on every pass.

Dosing depends on indication, age, hepatic function, and interacting drugs. Verify each order against current prescribing information and the patient’s opioid and CNS depressant exposure before administration.

Pediatrics: Safety and effectiveness of lorazepam tablets have not been established in children younger than 12 years per tablet labeling. IV status epilepticus dosing in children is not specified in the reviewed injection label for patients under 18 years—follow facility seizure protocol and specialist guidance.

Renal impairment: Not specified in the reviewed prescribing information for dedicated renal dose adjustment; observe usual precautions in impaired renal function per label.

Hepatic impairment: Not an absolute contraindication on the reviewed tablet label—use with caution in severe hepatic insufficiency and/or encephalopathy; dosage should be adjusted carefully with lower doses often sufficient per label.

Missed dose: If oversedated or new opioids are started, hold and clarify. For patients on continued benzodiazepine therapy, contact prescriber/pharmacy before abrupt gaps—do not double doses.

Pretreatment checks

• Screen the MAR and home med list for opioids, alcohol, sedating antihistamines, and other benzodiazepines—perform medication reconciliation on admission and after every transfer
• Assess respiratory rate, oxygenation (pulse oximetry per protocol), sedation level, and mental status; review history of COPD, severe pulmonary disease, or sleep apnea
• Confirm allergy to lorazepam or other benzodiazepines; verify tablet strength, route, indication, and whether a taper is in place if therapy is being reduced
• Screen for acute narrow-angle glaucoma and benzodiazepine hypersensitivity—contraindications per labeling; assess COPD, sleep apnea syndrome, and hepatic impairment as caution populations
• Review history of primary depressive disorder or psychosis—lorazepam is not recommended as primary therapy per label

Contraindications

• Acute narrow-angle glaucoma
• Hypersensitivity to benzodiazepines or any component of the formulation

Use with caution

• Compromised respiratory function (e.g., COPD, sleep apnea syndrome)
• Severe hepatic insufficiency and/or hepatic encephalopathy—lower doses may be sufficient
• Elderly or debilitated patients—sedation and unsteadiness increase with age per label
• Comorbid depression—suicide risk should be considered; adequate antidepressant therapy required per label

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Oral: Tablets (0.5 mg, 1 mg, 2 mg) swallowed with water; oral concentrate requires dilution per product instructions—high viscosity; mix with liquid immediately before use per concentrate labeling.

IV (status epilepticus): Administer slowly at 2 mg/min for the usual 4 mg adult dose; have airway equipment available; start IV fluids and monitor vitals per injection labeling. Do not give IV push at rates used for other drugs without verifying the order.

• Controlled substance (Schedule IV): follow institutional controlled-drug counting, wasting, and secure storage requirements
• Increase dose gradually when needed; increase the evening dose before daytime doses when titrating per label
• When combined with opioids or other CNS depressants, expect additive sedation—stagger assessments and avoid duplicate sedating PRNs
• Oral concentrate and tablet strengths are not interchangeable milligram-for-milligram without pharmacy verification

• Reduced anxiety or improved sleep when used for labeled indications—assess with patient report and observation, not sedation alone
• For IV status epilepticus, cessation of seizure activity within the observation window per orders—continue airway monitoring even after seizures stop
• Stable respiratory rate and oxygenation; perform neurological assessment and Glasgow Coma Scale when sedation or mental status changes
• Paradoxical agitation or insomnia should prompt prescriber review—more likely in children and older adults per label

Respiratory depression with benzodiazepines—especially plus opioids or alcohol—can progress to coma and death. Lorazepam may cause respiratory depression in COPD or sleep apnea. Abrupt discontinuation can precipitate withdrawal seizures. Escalate immediately.

• Respiratory rate below facility threshold, shallow breathing, apnea, or new difficulty breathing—hold lorazepam, support airway per protocol, rapid response
• SpO₂ drop, cyanosis, or inability to arouse the patient—treat as respiratory emergency; consider opioid co-ingestion
• Excessive sedation, ataxia, or confusion after a dose or dose increase
• Paradoxical agitation, aggression, hallucinations, or psychosis—discontinue gradually per label; more likely in children and older adults
• Breakthrough seizures or autonomic instability after missed doses, abrupt stop, or flumazenil—urgent prescriber and neurology input; flumazenil is contraindicated when benzodiazepines control a life-threatening condition such as status epilepticus
• Neonatal sedation or withdrawal signs if used late in pregnancy—escalate per maternal–child protocol

↔On a small screen, swipe or scroll sideways to see the full table.

Benzodiazepine overdosage ranges from drowsiness to coma. Severe cases may include respiratory depression. Combined overdose with opioids, alcohol, or other CNS depressants may be fatal. Markedly abnormal vital signs suggest polysubstance involvement.

Early signs

• Somnolence, confusion, dysarthria, ataxia, hypotonia, diminished reflexes
• Paradoxical agitation, irritability, or talkativeness (less common)
• Progressive respiratory depression and coma—especially with co-ingested opioids

Antidote and supportive care

Flumazenil is the specific benzodiazepine receptor antagonist indicated for complete or partial reversal of benzodiazepine sedation in overdosage management. It is an adjunct to airway management—not a substitute. Flumazenil may precipitate withdrawal and seizures, especially with chronic benzodiazepine use, mixed overdoses, or underlying seizure disorders; it is contraindicated when benzodiazepines were given for a potentially life-threatening condition (e.g., status epilepticus).

If opioids are co-involved, naloxone may reverse opioid-mediated respiratory depression per protocol—benzodiazepine effects may persist. Employ supportive measures including IV fluids and airway management per escalation pathways.

• Lorazepam vs alprazolam—sound-alike and look-alike risk in verbal and electronic orders; independent double-check name, strength, and indication
• Lorazepam vs diazepam vs clonazepam—all are benzodiazepines but differ in half-life, potency, and taper plans; verify MAR name and strength
• Ativan strength mix-ups—0.5 mg, 1 mg, and 2 mg tablets; independent double-check before administration
• Oral tablet vs oral concentrate vs IV—route and concentration errors are high-risk; IV status epilepticus doses are not interchangeable with oral anxiety doses
• Duplicate benzodiazepine therapy—home Ativan or alprazolam plus ordered lorazepam PRN is a common sedation stack
• Opioid + benzodiazepine orders—apply high-alert medication administration habits; document respiratory monitoring plan

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Respiratory rate, depth, and SpO₂—especially when opioids or alcohol are present or pulmonary disease is documented
• Sedation level (e.g., Pasero scale or facility tool), ability to arouse, and blood pressure for hypotension
• Mental status and anxiety/panic symptom response—sedation is not a proxy for therapeutic benefit
• Withdrawal signs if doses are delayed, reduced, or held: tremor, tachycardia, rebound anxiety, insomnia, or seizures—especially after weeks of regular use

Document

• Dose, route, time, indication, and patient response including respiratory status before and after
• Co-administered opioids or CNS depressants on the same shift; any hold and prescriber/pharmacist notification
• Controlled-drug count alignment; taper plan and patient education on why abrupt stops are dangerous

• Do not combine with alcohol, opioid pain medicines, or other sedating drugs unless your prescriber explicitly directs you—and report increased sleepiness immediately
• Do not drive or operate machinery until you know how lorazepam affects you, especially when starting or increasing dose or when taking opioids
• Never stop suddenly after regular use—withdrawal can be life-threatening and may include seizures; ask for a taper plan
• Keep medication secure (controlled substance); do not share tablets
• Seek urgent care for severe sleepiness, slow or troubled breathing, or inability to stay awake—and contact local poison control or toxicology services per your facility’s overdose guidance

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Rehearse NCLEX-style clinical judgment practice for lorazepam with a tabbed case (MAR, vitals, history, nursing notes), then priority action, cue recognition (SATA), respiratory trend interpretation, matrix urgency sorting, taper judgment, and overdose reversal cloze—stacked opioid–benzodiazepine respiratory depression is the safety thread; recognise cues → analyse → prioritise → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.